PHARMACEUTICAL INDUSTRY FACES AN "INNOVATION DEFICIT," HOFFMANN-LA ROCHE EXEC SUGGESTS; ALLIANCES WITH BIOTECH COULD MITIGATE DOWNWARD TREND IN NMEs
The pharmaceutical industry "doesn't generate enough interesting compounds that can satisfy and sustain its growth," Hoffmann-La Roche International R&D President Jurgen Drews, MD, declared in a Nov. 8 keynote speech to the Oppenheimer & Co. health care conference in New York City.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth